Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.2690
-0.0102 (-3.65%)
At close: Apr 1, 2025, 4:00 PM
0.2842
+0.0152 (5.66%)
After-hours: Apr 1, 2025, 4:19 PM EDT
Cyclacel Pharmaceuticals Stock Forecast
CYCC's stock price has decreased by -87.25% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Cyclacel Pharmaceuticals stock has a target of 11, which predicts an increase of 3,989.22% from the current stock price of 0.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Cyclacel Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $21 → $11 | Strong Buy | Maintains | $21 → $11 | +3,989.22% | May 3, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $16 → $21 | Strong Buy | Maintains | $16 → $21 | +7,706.69% | Dec 19, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $120 | Buy | Maintains | $120 | +44,509.67% | May 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $150 → $120 | Buy | Maintains | $150 → $120 | +44,509.67% | Mar 7, 2023 |
Financial Forecast
Revenue This Year
54.06K
from 420.00K
Decreased by -87.13%
Revenue Next Year
102.00K
from 54.06K
Increased by 88.68%
EPS This Year
-1.99
from -26.75
EPS Next Year
-1.20
from -1.99
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 55,650 | 105,000 | 105,000 | |
| Avg | 54,060 | 102,000 | 102,000 | |
| Low | 51,940 | 98,000 | 98,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -86.8% | 94.2% | 2.9% | |
| Avg | -87.1% | 88.7% | - | |
| Low | -87.6% | 81.3% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -2.05 | -1.24 | -1.18 | |
| Avg | -1.99 | -1.20 | -1.14 | |
| Low | -1.91 | -1.16 | -1.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.